Literature DB >> 12819469

Autoimmune lymphoproliferative syndrome.

Michael C Sneller1, Janet K Dale, Stephen E Straus.   

Abstract

Autoimmune lymphoproliferative syndrome arises early in childhood in people who inherit mutations in genes that mediate lymphocyte apoptosis, or programmed cell death. In the immune system, antigen-induced lymphocyte apoptosis maintains immune homeostasis by limiting lymphocyte accumulation and minimizing reactions against self-antigens. In autoimmune lymphoproliferative syndrome, defective lymphocyte apoptosis manifests as chronic, nonmalignant adenopathy and splenomegaly; the expansion of an unusual population of CD4-CD8- T cells; and the development of autoimmune disease. Most cases of autoimmune lymphoproliferative syndrome involve heterozygous mutations in the lymphocyte surface protein Fas (CD95, Apo1) that impair a major apoptotic pathway. Prospective evaluations of patients and their families have revealed an ever-expanding spectrum of autoimmune lymphoproliferative syndrome and its major complications.

Entities:  

Mesh:

Year:  2003        PMID: 12819469     DOI: 10.1097/00002281-200307000-00008

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  24 in total

Review 1.  New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey
Journal:  Curr Opin Pediatr       Date:  2012-02       Impact factor: 2.856

Review 2.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  Death receptor signal transducers: nodes of coordination in immune signaling networks.

Authors:  Nicholas S Wilson; Vishva Dixit; Avi Ashkenazi
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

4.  Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists.

Authors:  E de Vries
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 5.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

6.  cAMP-responsive element modulator α (CREMα) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease.

Authors:  Christian M Hedrich; Thomas Rauen; Jose C Crispin; Tomohiro Koga; Christina Ioannidis; Melissa Zajdel; Vasileios C Kyttaris; George C Tsokos
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

7.  Exposure to inorganic mercury in vivo attenuates extrinsic apoptotic signaling in Staphylococcal aureus enterotoxin B stimulated T-cells.

Authors:  Michael D Laiosa; Kevin G Eckles; Margaret Langdon; Allen J Rosenspire; Michael J McCabe
Journal:  Toxicol Appl Pharmacol       Date:  2007-06-19       Impact factor: 4.219

8.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

Review 9.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

Review 10.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.